Synthego Launches hfCas12Max High-Fidelity CRISPR Enzyme for Therapeutic Development

REDWOOD CITY, CA, June 3, 2024 –

Synthego introduces hfCas12Max, a high-fidelity CRISPR enzyme developed by HuidaGene Therapeutics and licensed exclusively by Synthego, designed to advance therapeutic genome editing with superior precision and efficiency. An enhanced alternative to traditional CRISPR nucleases, hfCas12Max is already being utilized in clinical trials, underscoring its potential in advancing real-world therapeutic applications. With this novel CRISPR solution, Synthego has streamlined the licensing process to make it more efficient and cost-effective, allowing developers quick and easy access to this cutting-edge technology for advancing their therapeutic programs.

The innovative hfCas12Max CRISPR enzyme is specifically engineered for applications requiring exceptional accuracy, such as gene and cell therapy development. By minimizing unintended edits while retaining robust on-target activity, hfCas12Max meets the stringent demands of translational research and therapeutic programs. Paired with Synthego's best-in-class gRNAs, optimized for seamless integration with hfCas12Max, this novel system ensures consistent and high-quality results that meet the rigorous demands of clinical applications.

Synthego's offering underscores its commitment to enabling therapeutic innovation and driving advancements in the life sciences industry. By pairing advanced genome editing tools like hfCas12Max with tailored sub-licensing solutions, the company is helping researchers and developers accelerate progress toward groundbreaking therapies. For more details on hfCas12Max, sub-licensing opportunities, and Synthego's specialized gRNAs, visit the hfCas12Max product page or chat with our CRISPR experts.